首页> 外文期刊>JMIR Mental Health >Mobile-Assisted Cognitive Behavioral Therapy for Negative Symptoms: Open Single-Arm Trial With Schizophrenia Patients
【24h】

Mobile-Assisted Cognitive Behavioral Therapy for Negative Symptoms: Open Single-Arm Trial With Schizophrenia Patients

机译:用于消极症状的移动辅助认知行为疗法:用精神分裂症患者开放单臂试验

获取原文
           

摘要

Background Negative symptoms are an important unmet treatment need for schizophrenia. This study is a preliminary, open, single-arm trial of a novel hybrid intervention called mobile-assisted cognitive behavioral therapy for negative symptoms (mCBTn). Objective The primary aim was to test whether mCBTn was feasible and could reduce severity of the target mechanism, defeatist performance attitudes, which are associated with experiential negative symptoms and poor functioning in schizophrenia. Methods Participants with schizophrenia or schizoaffective disorder (N=31) who met prospective criteria for persistent negative symptoms were enrolled. The blended intervention combines weekly in-person group therapy with a smartphone app called CBT2go. The app extended therapy group skills, including recovery goal setting, thought challenging, scheduling of pleasurable activities and social interactions, and pleasure-savoring interventions to modify defeatist attitudes and improve experiential negative symptoms. Results Retention was excellent (87% at 18 weeks), and severity of defeatist attitudes and experiential negative symptoms declined significantly in the mCBTn intervention with large effect sizes. Conclusions The findings suggest that mCBTn is a feasible and potentially effective treatment for experiential negative symptoms, if confirmed in a larger randomized controlled trial. The findings also provide support for the defeatist attitude model of experiential negative symptoms and suggest that blended technology-supported interventions such as mCBTn can strengthen and shorten intensive psychosocial interventions for schizophrenia. Trial Registration ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT03179696","term_id":"NCT03179696"}} NCT03179696 ; https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT03179696","term_id":"NCT03179696"}} NCT03179696
机译:背景,阴性症状是精神分裂症的重要未满足的治疗需求。本研究是初步,开放的单手臂试验,称为移动辅助认知行为治疗的新型杂种干预,用于消极症状(MCBTN)。目的主要目的是测试MCBTN是否可行,可以减少目标机制的严重程度,失败的绩效态度,这些态度与体验性的阴性症状和精神分裂症功能不佳。方法参与持续阴性症状前瞻性标准的精神分裂症或精神分裂症或SchizoAfferciverive疾病的参与者进行了入围。混合干预与智能手机应用程序与名为CBT2GO的智能手机应用程序相结合。该应用扩展治疗组技能,包括恢复目标设定,思想挑战,安排愉快的活动和社会互动,以及修改失败主义态度和改善体验消减症状的乐趣口味干预措施。结果保留优异(87%在18周内),并且失败者态度和体验性消极症状的严重程度在MCBTN干预中具有大量效果大小的显着下降。结论研究表明,如果在较大的随机对照试验中确认,MCBTN是对体验性症状的可行和潜在有效的治疗方法。该调查结果还为体验性消极症状的失败态度模型提供了支持,并提出了混合技术支持的干预措施,如MCBTN,可以加强和缩短精神分裂症的密集心理社会干预措施。试验登记ClinicalTrials.gov {“类型”:“临床 - 试验”,“attrs”:{“text”:“nct03179696”,“term_id”:“nct03179696”}} nct03179696; https://clinicaltrials.gov/ct2/show/ {“type”:“临床试验”,“attrs”:{“text”:“nct03179696”,“term_id”:“nct03179696”}} NCT03179696

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号